Earnings and Clinical Wins Fuel Hong Kong Biotech Recovery
Global Report·- Driven by strong earnings and pipeline milestones, the Hong Kong stock biomedicine sector shows a significant recovery trend this year. - JD Health reported 2026 first-half total revenue of 40.888 billion RMB, with Non-IFRS operating profit surging 40.3% to 3.5 billion RMB. - Zai Lab advanced its innovative drug pipeline as VYVGART Hytrulo met its Phase III clinical trial primary endpoint and Zoci secured FDA orphan drug designation.